1. HBW Insight
  2. >>Archive

Jury Still Out On Feminine-Hygiene Talc Safety, Except In The Courts

 
• By Ryan Nelson

Health and scientific authorities have taken various positions on the possible link between perineal talcum-powder use and ovarian cancer, including that the substance is safe as used, is "possibly carcinogenic" and that data is insufficient to allow for a conclusive assessment. Juries in J&J talc trials have been more convinced of the talc-cancer correlation and the firm's negligence in not warning consumers about risks.

Health and scientific authorities may be unconvinced that non-asbestiform talc poses cancer risks, but juries in the US are finding evidence more compelling in recent cases pitting ovarian-cancer victims against Johnson & Johnson.

St

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from HBW Insight

Makary’s Reorganization Decision A Turning Point For US FDA?

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s disavowal of a proposed reorganization plan may be an important turning point in the Trump Administration. The move does not improve the situation, but may mean the administration stops actively making things worse.

C&D Divesting Flawless, Spinbrush Lines, Says Gummy Vitamin Brands Might Not Stick

 
• By Malcolm Spicer

C&D reports Q1 net sales dropped 2.4% to $1.48bn, below its guidance for around 1% growth. Its brands’ sales at retail and market share grew in the quarter, but “experienced slowing category growth in the US market” as retailers reduced inventory levels.

Herbalife Expects No ‘Material’ Impact From China Tariff, Recent Deals To Bring ‘New Era’ Of Growth

 
• By Malcolm Spicer

Herbalife expects little impact from increased tariffs on imports from China but strong boosts from acquiring Pro2col Health and Pruvit Ventures Inc. and 51% ownership of Link BioSciences.